Association of serotonin transporter (SLC6A4) & receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study

Background & objectives: Genetic factors have potential of predicting response to antidepressants in patients with major depressive disorder (MDD). In this study, an attempt was made to find an association between response to escitalopram in patients with MDD, and serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms. Methods: Fifty five patients diagnosed as suffering from MDD, were selected for the study. The patients were treated with escitalopram over a period of 6-8 wk. Severity of depression, response to treatment and side effects were assessed using standardised instruments. Genetic variations from HTR1A (rs6295), HTR2A (rs6311 and rs6313) and SLC6A4 (44 base-pair insertion/deletion at 5-HTTLPR) were genotyped. The genetic data of the responders and non-responders were compared to assess the role of genetic variants in therapeutic outcome. Results: Thirty six (65.5%) patients responded to treatment, and 19 (34.5%) had complete remission. No association was observed for genotype and allelic frequencies of single nucleotide polymorphisms (SNPs) among remitter/non-remitter and responder/non-responder groups, and six most common side-effects, except memory loss which was significantly associated with rs6311 (P =0.03). Interpretation & conclusions: No significant association was found between the SNPs analysed and response to escitalopram in patients with MDD though a significant association was seen between the side effect of memory loss and rs6311. Studies with larger sample are required to find out genetic basis of antidepressant response in Indian patients.

[1]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[2]  T. Hergueta,et al.  The mini international neuropsychiatric interview , 1998, European Psychiatry.

[3]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[4]  Arif Ali,et al.  Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study , 2008, Indian journal of psychiatry.

[5]  Xiao-hong Ma,et al.  Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response , 2009, Psychopharmacology.

[6]  S. Tsai,et al.  Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder , 2006, The Pharmacogenomics Journal.

[7]  B. Carroll,et al.  Serotonin transporter gene polymorphism and antidepressant response , 2000, Neuroreport.

[8]  M. Rietschel,et al.  Moderation of antidepressant response by the serotonin transporter gene , 2009, British Journal of Psychiatry.

[9]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[10]  R. Yoshimura,et al.  Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients , 2009, Human psychopharmacology.

[11]  I. M. G. Consortium,et al.  Genetic landscape of the people of India: a canvas for disease gene exploration , 2008 .

[12]  T. Lehtimäki,et al.  Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? , 2011, European Archives of Psychiatry and Clinical Neuroscience.

[13]  J. Ballenger.  Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample , 2008 .

[14]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[15]  A. Serretti,et al.  Pharmacogenetic studies in depression: a proposal for methodologic guidelines , 2008, The Pharmacogenomics Journal.

[16]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[17]  N. Fineberg,et al.  SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OCD , 1992, Clinical neuropharmacology.

[18]  S. Mace,et al.  Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression , 2000, Expert opinion on pharmacotherapy.

[19]  T. Lehtimäki,et al.  5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression , 2009, Neuroreport.

[20]  Harold I. Kaplan,et al.  Comprehensive textbook of psychiatry/III , 1980 .

[21]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.